Ballentine Partners LLC Makes New $263,000 Investment in Smith & Nephew SNATS, Inc. $SNN

Key Points

• Ballentine Partners LLC made a new investment in Smith & Nephew SNATS, purchasing 8,573 shares valued at approximately $263,000 in the second quarter.
• Multiple institutional investors have significantly increased their positions in Smith & Nephew, with some firms boosting their holdings by over 3,400%.
• Smith & Nephew announced a semi-annual dividend of $0.285 per share, with a yield of 210.0%, and a payout ratio of 41.20%.

Ballentine Partners LLC bought a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,573 shares of the medical equipment provider's stock, valued at approximately $263,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hexagon Capital Partners LLC boosted its position in Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 406 shares during the period. Richards Merrill & Peterson Inc. grew its position in shares of Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 1,000 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,701 shares during the period. Banque Transatlantique SA bought a new stake in Smith & Nephew SNATS in the 1st quarter valued at about $52,000. Finally, Opal Wealth Advisors LLC acquired a new position in Smith & Nephew SNATS during the 1st quarter valued at about $73,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

SNN opened at $35.44 on Monday. The business has a 50 day moving average price of $35.65 and a two-hundred day moving average price of $30.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The company has a market capitalization of $15.43 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 0.98 and a beta of 0.70. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio (DPR) is currently 41.20%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a report on Monday, August 18th. Wall Street Zen upgraded Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 30th. Six research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $36.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.